World's Best Scientists 2026 revealed!
Jennifer R. Brown

Jennifer R. Brown

D-Index & Metrics

Medicine

D-Index
97
Citations
39718
World Ranking
9184
National Ranking
4738

Research.com Recognitions

  • 2008 - Fellow of the Royal Society of Canada Academy of Social Sciences

Overview

Jennifer R. Brown is affiliated with Harvard University in the United States and has a research focus within the field of Medicine. Their work spans multiple subfields including Genetics, Pathology and Forensic Medicine, Immunology, Oncology, and Hematology.

Their main research topics include:

  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Immunodeficiency and Autoimmune Disorders
  • Advanced Breast Cancer Therapies
  • CAR-T cell therapy research
  • PI3K/AKT/mTOR signaling in cancer

Jennifer R. Brown has published extensively in various scientific journals. Frequent publication venues include:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Blood Advances
  • Journal of Clinical Oncology
  • Hematological Oncology

Notable recent papers authored or coauthored by Jennifer R. Brown are:

  • "Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia," 2022, New England Journal of Medicine
  • "PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer," 2023, Molecular Cancer
  • "PI3K inhibitors are finally coming of age," 2021, Nature Reviews Drug Discovery
  • "Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study," 2021, The Lancet
  • "Outcomes of COVID-19 in patients with CLL: a multicenter international experience," 2020, Blood

Their frequent coauthors include:

  • Matthew S. Davids
  • Stacey M. Fernandes
  • Constantine S. Tam
  • Paolo Ghia
  • Wojciech Jurczak

Jennifer R. Brown received the award Fellow of the Royal Society of Canada in 2008, recognized by the Academy of Social Sciences.

Best Publications

  • Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

    Andrew W. Roberts;Matthew S. Davids;John M. Pagel;Brad S. Kahl

  • Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

    J. C. Byrd;J. R. Brown;Susan O'Brien;J. C. Barrientos

  • Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia

    Dan A. Landau;Scott L. Carter;Petar Stojanov;Petar Stojanov;Aaron McKenna

  • SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia

    Lili Wang;Michael S. Lawrence;Youzhong Wan;Petar Stojanov

  • Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Bonnie Harrington;Susan O'Brien;Jeffrey A. Jones

  • Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

    Andrew W. Roberts;John F. Seymour;John F. Seymour;Jennifer R. Brown;William G. Wierda

  • Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

    Jennifer A Woyach;Amy S Ruppert;Nyla A Heerema;Weiqiang Zhao

  • Targeting transcription regulation in cancer with a covalent CDK7 inhibitor

    Nicholas Kwiatkowski;Tinghu Zhang;Peter B. Rahl;Brian J Abraham

  • Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

    Jennifer R. Brown;John C. Byrd;Steven E. Coutre;Don M. Benson

  • Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737

    Victoria Del Gaizo Moore;Jennifer R. Brown;Michael Certo;Tara M. Love

  • A Defect in Nurturing in Mice Lacking the Immediate Early Gene fosB

    Jennifer R Brown;Jennifer R Brown;Hong Ye;Hong Ye;Roderick T Bronson;Pieter Dikkes

  • Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia

    Laura Z. Rassenti;Sonia Jain;Michael J. Keating;William G. Wierda

  • Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia

    Akinori Yoda;Yuka Yoda;Sabina Chiaretti;Michal Bar-Natan

  • Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

    Talha Munir;Jennifer R. Brown;Susan O'Brien;Jacqueline C. Barrientos

  • Locally Disordered Methylation Forms the Basis of Intratumor Methylome Variation in Chronic Lymphocytic Leukemia

    Dan Avi Landau;Dan Avi Landau;Kendell Clement;Kendell Clement;Kendell Clement;Michael Johannes Ziller;Michael Johannes Ziller;Patrick Boyle

  • Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.

    Susan O'Brien;Susan O'Brien;Jeffrey A Jones;Steven E Coutre;Anthony R Mato;Anthony R Mato

  • MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.

    Lian Xu;Zachary R. Hunter;Guang Yang;Yangsheng Zhou

  • FosB mutant mice: loss of chronic cocaine induction of Fos-related proteins and heightened sensitivity to cocaine's psychomotor and rewarding effects.

    Noboru Hiroi;Jennifer R. Brown;Colin N. Haile;Hong Ye

  • Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

    Jan A. Burger;Dan A. Landau;Amaro Taylor-Weiner;Ivana Bozic

  • Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.

    Anthony R Mato;Nirav N Shah;Wojciech Jurczak;Chan Y Cheah

Frequent Co-Authors

Donna Neuberg
Donna Neuberg Harvard University
John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute
Susan O'Brien
Susan O'Brien University of California, Irvine
Thomas J. Kipps
Thomas J. Kipps University of California, San Diego
Catherine J. Wu
Catherine J. Wu Harvard University
Peter Hillmen
Peter Hillmen St James's University Hospital
Arnold S. Freedman
Arnold S. Freedman Harvard University
Richard R. Furman
Richard R. Furman NewYork–Presbyterian Hospital
Steven Coutre
Steven Coutre Stanford University
William G. Wierda
William G. Wierda The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare but seeking alternative or complementary career paths to medicine, a range of online degrees and bridge programs are available. For example, registered nurses wishing to advance their practice can explore rn to fnp programs, which allow RNs to become Family Nurse Practitioners through flexible, reputable online options.

Nutrition is another growing field. Those passionate about diet, wellness, and prevention can consider online degrees in nutrition as a foundation for careers as dietitians, health educators, or public health specialists.

Administration and leadership roles in healthcare are also accessible through quality online education. Prospective managers should look for which online healthcare administration programs have cahme accreditation? to ensure their degree meets high industry standards.

Additionally, nurses aiming to obtain a bachelor’s degree may benefit from rn to bsn programs no clinicals, which offer convenient and accelerated pathways without extra clinical requirements.

These options provide valuable, flexible career pathways for aspiring healthcare professionals who want alternatives to traditional, on-campus medical education in the USA.

Best Scientists Citing Jennifer R. Brown

Trending Scientists

Recently Published Articles